Antistaphylococcal activity of DNA-interactive pyrrolobenzodiazepine (PBD) dimers and PBD-biaryl conjugates

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 7, 2012, Pages 1683-1696

  Rahman, Khondaker M ^a   Rosado, Helena ^a   Moreira, Joao B ^a   Feuerbaum, Eva Anne ^a   Fox, Keith R ^b   Stecher, Eva ^a   Howard, Philip W ^c   Gregson, Stephen J ^c   James, Colin H ^a   De la Fuente, Maria ^a   Waldron, Denise E ^d   Thurston, David E ^a,c   Taylor, Peter W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

DNA adduct formation; MRSA; Pyrrolobenzodiazepine dimers; Pyrrolobenzodiazepine biaryl conjugates

Indexed keywords

BENZODIAZEPINE DERIVATIVE; DEOXYRIBONUCLEASE I; DIMER; DOUBLE STRANDED DNA; PYRROLOBENZODIAZEPINE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GENE; BACTERICIDAL ACTIVITY; BINDING SITE; CONJUGATE; COVALENT BOND; CYTOTOXICITY TEST; DNA BINDING; DNA CROSS LINKING; DNA FOOTPRINTING; DNA HELIX; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; PHENOTYPE; SUBSTITUTION REACTION;

ANTI-BACTERIAL AGENTS; BENZODIAZEPINES; BINDING SITES; DNA FOOTPRINTING; DNA, BACTERIAL; GENE EXPRESSION PROFILING; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROARRAY ANALYSIS; MICROBIAL VIABILITY; MOLECULAR DYNAMICS SIMULATION; PYRROLES;

EID: 84862690637     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks127     Document Type: Article

References (42)

1. Greenwood D. Antimicrobial Drugs - Chronicle of a Twentieth Century Medical Triumph. Oxford: Oxford University Press, 2008.
2. Leimgruber W, Stefanovic V, Schenker F et al. Isolation and characterization of anthramycin, a new antitumor antibiotic. J Amer Chem Soc 1965; 87: 5791-3.
3. Arima K, Kosaka M, Tamura G et al. Studies on tomaymycin, a new antibiotic. I. Isolation and properties of tomaymycin. J Antibiot (Tokyo) 1972; 25: 437-44.
4. Brazhnikova MG, Konstantinova NV, Mesentsev AS. Sibiromycin: isolation and characterization. J Antibiot (Tokyo) 1972; 25: 668-73.
5. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 2004; 10 Suppl 12: S122-9.
6. Davies J, Davies G. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 2010; 74: 417-33.
7. Li J, Nation RL, Turnidge JD et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6: 589-601.
8. Hadjivassileva T, Thurston DE, Taylor PW. Pyrrolobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria. J Antimicrob Chemother 2005; 56: 513-8.
9. Hadjivassileva T, Stapleton PD, Thurston DE et al. Interactions of pyrrolobenzodiazepine dimers and duplex DNA from methicillinresistant Staphylococcus aureus. Int J Antimicrob Agents 2007; 290: 672-8.
10. Doyle M, Feuerbaum E-A, Fox KR et al. Response of Staphylococcus aureus to subinhibitory concentrations of a sequence-selective, DNA minor groove cross-linking pyrrolobenzodiazepine dimer. J Antimicrob Chemother 2009; 64: 949-59.
11. Puvvada MS, Forrow SA, Hartley JA et al. Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4]-benzodiazepines. Biochemistry 1997; 36: 2478-84.
12. Smellie M, Bose DS, Thompson AS et al. Sequence-selective recognition of duplex DNA through covalent interstrand cross-linking: kinetic and molecular modeling studies with pyrrolobenzodiazepine dimers. Biochemistry 2003; 42: 8232-9.
13. Martin C, Ellis T, McGurk CJ et al. Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies. Biochemistry 2005; 44: 4135-47.
14. Rosado H, Rahman K, Feuerbaum E-A et al. The minor groove-binding agent ELB-21 forms multiple interstrand and intrastrand covalent cross-links with duplex DNA and displays potent bactericidal activity against methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2011; 66: 985-96.
15. Pepper CJ, Hambly RM, Fegan CD et al. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill. Cancer Res 2004; 64: 6750-5.
16. Arnould S, Spanswick VJ, Macpherson JS et al. Time-dependent cytotoxicity induced by SJG-136 (NSC 694501): influence of the rate of interstrand cross-link formation on DNA damage signaling. Mol Cancer Ther 2006; 5: 1602-9.
17. Rahman KM, Thompson AS, James CH et al. The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links. J Amer Chem Soc 2009; 131: 13756-66.
18. Haywood-Farmer E, Otto SP. The evolution of genomic base composition in bacteria. Evolution 2003; 57: 1783-92.
19. Wells G, Martin CRH, Howard PW et al. Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepinepoly(N-methylpyrrole) conjugates. J Med Chem 2006; 49: 5442-61.
20. Stapleton PD, Shah S, Anderson JC et al. Modulation of β-lactam resistance in Staphylococcus aureus by catechins and gallates. Int J Antimicrob Agents 2004; 23: 462-7.
21. Skehan P, Storeng R, Scudiero DA et al. New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 1990; 82: 1107-12.
22. Gregson SJ, Howard PW, Gullick DR et al. Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers. J Med Chem 2004; 47: 1161-74.
23. Thurston DE, Bose DS, Howard PW et al. Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c] [1,4]benzodiazepines. J Med Chem 1999; 42: 1951-64.
24. Antonow D, Thurston DE. Synthesis of DNA-interactive pyrrolo[2,1-c] [1,4]benzodiazepines (PBDs). Chem Rev 2011; 111: 2815-64.
25. Tiberghien AC, Evans DA, Kiakos K et al. An asymmetric C8/C8'-tripyrrole-linked sequence-selective pyrrolo[2,1-c][1,4] benzodiazepine (PBD) dimer DNA interstrand cross-linking agent spanning 11 DNA base pairs. Bioorg Med Chem Lett 2008; 18: 2073-7.
26. Howard PW, Chen Z, Gregson SJ et al. Synthesis of a novel C2/ C2'-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced reaction rate. Bioorg Med Chem Lett 2009; 19: 6463-6.
27. Antonow D, Kaliszczak M, Kang GD et al. Structure-activity relationships of monomeric C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor agents. J Med Chem 2010; 53: 2927-41.
28. Hampshire AJ, Rusling DA, Broughton-Head VJ et al. Footprinting: a method for determining the sequence selectivity, affinity and kinetics of DNA-binding ligands. Methods 2007; 42: 128-40.
29. Hampshire AJ, Fox KR. Preferred binding sites for the bifunctional intercalator TANDEM determined using DNA fragments that contain every symmetrical hexanucleotide sequence. Anal Biochem 2008; 374: 298-303.
30. Witney AA, Marsden GL, Holden MT et al. Design, validation, and application of a seven-strain Staphylococcus aureus PCR product microarray for comparative genomics. Appl Environ Microbiol 2005; 71: 7504-14.
31. Case DA, Darden TA, Cheatham TE III et al. AMBER 9. San Francisco: University of California, 2006.
32. Humphrey W, Dalke A, Schulten K. VMD - visual molecular dynamics. J Molec Graph 1996; 14: 33-8.
33. Pettersen EF, Goddard TD, Huang CC et al. UCSF Chimera - a visualization system for exploratory research and analysis. J Comput Chem 2004; 25: 1605-12.
34. Lebbink JHG, Georgijevic D, Natrajan G et al. Dual role of MutS glutamate 38 in mismatch discrimination and in the authorization of repair. EMBO J 2006; 25: 409-19.
35. Nohmi T. Environmental stress and lesion-bypass DNA polymerases. Ann Rev Microbiol 2006; 60: 231-53.
36. Hartley JA, Hamaguchi A, Coffils M et al. SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity. Cancer Res 2010; 70: 6849-58.
37. Baba T, Takeuchi F, Kuroda M et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359: 1819-27.
38. Rahman KM, James CH, Thurston DE. Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers. Nucl Acids Res 2011; 39: 5800-12.
39. Hartley JA, Spanswick VJ, Brooks N et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumour activity. Cancer Res 2004; 64: 6693-9.
40. Alley MC, Hollingshead MG, Pacula-Cox CM et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumour activity: part 2: efficacy evaluations. Cancer Res 2004; 64: 6700-6.
41. Redon CE, Nakamura AJ, Zhang YW et al. Histone yH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 2010; 16: 4532-42.
42. Janjigian Y, Lee W, Kris M et al. A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer Chemother Pharmacol 2010; 65: 833-8.